Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus (131)I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016

PURPOSE: SWOG S0016 was a phase III randomized study that compared the safety and efficacy of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) with CHOP-RIT (CHOP followed by consolidation with iodine-133–tositumomab radioimmunotherapy) for previously untreated pati...

詳細記述

保存先:
書誌詳細
出版年:J Clin Oncol
主要な著者: Shadman, Mazyar, Li, Hongli, Rimsza, Lisa, Leonard, John P., Kaminski, Mark S., Braziel, Rita M., Spier, Catherine M., Gopal, Ajay K., Maloney, David G., Cheson, Bruce D., Dakhil, Shaker, LeBlanc, Michael, Smith, Sonali M., Fisher, Richard I., Friedberg, Jonathan W., Press, Oliver W.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2018
主題:
ORIGINAL REPORTS
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6553811/
https://ncbi.nlm.nih.gov/pubmed/29356608
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.74.5083
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料